{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T07:23:40Z","timestamp":1790753020721,"version":"4.1.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"crossref","award":["K12 CA 133250"],"award-info":[{"award-number":["K12 CA 133250"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1016\/j.breast.2012.12.006","type":"journal-article","created":{"date-parts":[[2013,1,23]],"date-time":"2013-01-23T18:32:07Z","timestamp":1358965927000},"page":"525-531","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":113,"title":["Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab era"],"prefix":"10.1016","volume":"22","author":[{"given":"Erin M.","family":"Olson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie S.","family":"Najita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Sohl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amal","family":"Arnaout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harold J.","family":"Burstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric P.","family":"Winer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy U.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.breast.2012.12.006_bib1","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.breast.2012.12.006_bib2","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1200\/JCO.1999.17.9.2639","article-title":"Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease","volume":"17","author":"Cobleigh","year":"1999","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.breast.2012.12.006_bib3","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1200\/JCO.2002.20.3.719","article-title":"Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer","volume":"20","author":"Vogel","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"10.1016\/j.breast.2012.12.006_bib4","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1200\/JCO.2001.19.10.2722","article-title":"Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer","volume":"19","author":"Burstein","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.breast.2012.12.006_bib5","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1200\/JCO.2008.19.9844","article-title":"Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review","volume":"28","author":"Dawood","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"19","key":"10.1016\/j.breast.2012.12.006_bib6","doi-asserted-by":"crossref","first-page":"4265","DOI":"10.1200\/JCO.2005.04.173","article-title":"Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group","volume":"23","author":"Marty","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"18","key":"10.1016\/j.breast.2012.12.006_bib7","doi-asserted-by":"crossref","first-page":"2786","DOI":"10.1200\/JCO.2005.04.1764","article-title":"Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer","volume":"24","author":"Robert","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"10.1016\/j.breast.2012.12.006_bib8","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1093\/annonc\/mdl476","article-title":"A\u00a0review of the use of trastuzumab (Herceptin) plus vinorelbine in metastatic breast cancer","volume":"18","author":"Chan","year":"2007","journal-title":"Ann Oncol"},{"issue":"17","key":"10.1016\/j.breast.2012.12.006_bib9","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1200\/JCO.2010.32.3550","article-title":"Breast cancer adjuvant therapy: time to consider its time-dependent effects","volume":"29","author":"Jatoi","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.breast.2012.12.006_bib10","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1200\/JCO.2008.19.6618","article-title":"Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German breast group 26\/breast international group 03-05 study","volume":"27","author":"von Minckwitz","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"10.1016\/j.breast.2012.12.006_bib11","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1200\/JCO.2008.21.4437","article-title":"Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer","volume":"28","author":"Blackwell","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.breast.2012.12.006_bib12","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/annonc\/mdr061","article-title":"Responses to subsequent anti-HER2 therapy after treatment with trastuzumab-DM1 in women with HER2-positive metastatic breast cancer","volume":"23","author":"Olson","year":"2012","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.breast.2012.12.006_bib13","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1200\/JCO.2010.31.6679","article-title":"Trastuzumab-DM1: building a chemotherapy-free road in the treatment of human epidermal growth factor receptor 2-positive breast cancer","volume":"29","author":"Isakoff","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"26","key":"10.1016\/j.breast.2012.12.006_bib14","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1056\/NEJMoa064320","article-title":"Lapatinib plus capecitabine for HER2-positive advanced breast cancer","volume":"355","author":"Geyer","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.breast.2012.12.006_bib15","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.2009.25.8707","article-title":"Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer","volume":"28","author":"Burstein","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.breast.2012.12.006_bib16","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.1002\/cncr.11436","article-title":"Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma","volume":"97","author":"Bendell","year":"2003","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.breast.2012.12.006_bib17","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1158\/1078-0432.CCR-06-2478","article-title":"Brain metastases: the HER2 paradigm","volume":"13","author":"Lin","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.breast.2012.12.006_bib18","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.clbc.2011.03.024","article-title":"A\u00a0phase II study of sagopilone (ZK 219477; ZK-EPO) in patients with breast cancer and brain metastases","volume":"11","author":"Freedman","year":"2011","journal-title":"Clin Breast Cancer"},{"issue":"2","key":"10.1016\/j.breast.2012.12.006_bib19","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.breast.2012.12.006_bib20","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1002\/cncr.22867","article-title":"The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer","volume":"110","author":"Chia","year":"2007","journal-title":"Cancer"},{"issue":"14","key":"10.1016\/j.breast.2012.12.006_bib21","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1200\/JCO.2011.40.2545","article-title":"Maximizing human epidermal growth factor receptor 2 inhibition: a new oncologic paradigm in the era of targeted therapy","volume":"30","author":"Olson","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.breast.2012.12.006_bib22","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3816\/CBC.2009.n.005","article-title":"Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design","volume":"9","author":"Kassam","year":"2009","journal-title":"Clin Breast Cancer"},{"issue":"1","key":"10.1016\/j.breast.2012.12.006_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10549-012-2328-6","article-title":"Emerging treatment options for the management of brain metastases in patients with HER2-positive metastatic breast cancer","volume":"137","author":"Chien","year":"2012","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"10.1016\/j.breast.2012.12.006_bib24","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s11060-011-0629-y","article-title":"Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases","volume":"105","author":"Lin","year":"2011","journal-title":"J\u00a0Neurooncol"},{"issue":"9","key":"10.1016\/j.breast.2012.12.006_bib25","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1002\/cncr.25771","article-title":"Multifactorial central nervous system recurrence susceptibility in patients with HER2-positive breast cancer","volume":"117","author":"Musolino","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.breast.2012.12.006_bib26","doi-asserted-by":"crossref","unstructured":"Blackwell K, Burstein H, Sledge G, Stein S, Ellis C, Casey M, et\u00a0al. Updated survival analysis of a randomized study of lapatinib alone or in combination with trastuzumab in women with HER2-positive metastatic breast cancer progressing on trastuzumab therapy. In San Antonio breast conference symposium. San Antonio, TX; 2009.","DOI":"10.1158\/0008-5472.SABCS-09-61"},{"issue":"10","key":"10.1016\/j.breast.2012.12.006_bib27","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1038\/nrclinonc.2011.114","article-title":"The ethical use of mandatory research biopsies","volume":"8","author":"Olson","year":"2011","journal-title":"Nat Rev Clin Oncol"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977612002500?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977612002500?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:32:21Z","timestamp":1760776341000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977612002500"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["S0960977612002500"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2012.12.006","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2013,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab era","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2012.12.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}